ADNAN JALIL

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R.4, the Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011, legislation would repeal provision of the Patient Protection and Affordable Care Act (PPACA) that expanded 1099 tax reporting requirements for businesses that purchase goods and services of more than $600-became law 4/14/11; opposed Senate amendment 392 to S. 782 which would delay implementation of the of new caps on credit card fees. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

S. 312 and H.R. 605, the Patients' Freedom to Choose Act

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 4, S. 18 and S. 72, bills which would repeal the expanded 1099 form filing requirements; H.R. 605 and S. 312, Patients Freedom to Choose Act of 2011, repeals provisions of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 that restrict payments from health savings accounts, medical savings accounts, and health flexible spending arrangements for medications to prescription drugs and insulin only; sent letter to House and Senate Members in support of allowing the Federal Reserve to finalize the rule which would limit the amount of interchange (or swipe) fees that banks could charge on debit card transactions.

S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

H.R. 4, S. 18 and S. 72, bills which would repeal the expanded 1099 form filing requirements; H.R. 605 and S. 312, Patients Freedom to Choose Act of 2011, repeals provisions of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 that restrict payments from health savings accounts, medical savings accounts, and health flexible spending arrangements for medications to prescription drugs and insulin only; sent letter to House and Senate Members in support of allowing the Federal Reserve to finalize the rule which would limit the amount of interchange (or swipe) fees that banks could charge on debit card transactions.